Written by Julie Fricke (Systematic Review Analyst) and Neil Webb (Head of Systematic Review) Systematic Reviews – The Problem Although considered the gold standard of quality research, systematic literature reviews (SLRs) are very resource intensive (e.g. long...
Written by Chris Hellmund, Senior Medical Writer In a previous post, we discussed the origins of the NICE Highly Specialised Technologies (HST) process for the evaluation of therapies for rare diseases. In this blog, we examine the key differences between the Single...
Written by Chris Hellmund, Senior Medical Writer Origins of the Highly Specialised Technologies (HST) process Treatments for very rare conditions represent a unique challenge to payers. Extremely low patient numbers mean that often only Phase 1/2 trial data are...
Written by Neil Webb (Head of Systematic Review) and Chris Hellmund (Senior Medical Writer) On the 1st April 2017, the National Institute for Health and Care Excellence (NICE) introduced a fast-track appraisal (FTA) process, with the aim of providing quicker access...
Written by David Trueman, Director The rate at which future costs and outcomes are discounted has long stood at 3.5% for UK HTA agencies (1,2). The source of this discount rate is the Social Time Preference Rate (STPR), presented in previous versions of the Treasury’s...
Written by Juliet Mumby-Croft, Director Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments...
